The present disclosure relates to devices for repairing or regenerating a meniscus or a portion of a meniscus in a knee.
It is known to use various collageneous scaffolds to provide a matrix for repair and regeneration of damaged tissue. U.S. Pat. No. 6,042,610 to ReGen Biologics, hereby incorporated by reference, discloses the use of a device comprising a bioabsorbable material made at least in part from purified natural fibers of collagen or glycosaminoglycans. The purified natural fibers are cross-linked to form the device of U.S. Pat. No. 6,042,610. The device can be used to provide augmentation for a damaged meniscus. Related U.S. Pat. Nos. 5,735,903, 5,681,353, 5,306,311, 5,007,934, and 4,880,429 also disclose a meniscal augmentation device for establishing a scaffold adapted for ingrowth of meniscal fibrochondrocyts.
It is also known to use naturally occurring extracellular matrices (ECMs) to provide a scaffold for tissue repair and regeneration. One such ECM is small intestine submucosa (SIS). SIS has been described as a natural biomaterial used to repair, support, and stabilize a wide variety of anatomical defects and traumatic injuries. See, for example, Cook® Online New Release provided by Cook Biotech of Bloomington, Ind., a copy of which can be found at their online website. The SIS material is reported to be a naturally-occurring collagenous matrix derived from porcine small intestinal submucosa that models the qualities of its host when implanted in human soft tissues. Further, it is taught that the SIS material provides a natural matrix with a three-dimensional structure and biochemical composition that attracts host cells and supports tissue remodeling. SIS products, such as Oasis material and Surgisis material, are commercially available from Cook Biotech, Bloomington, IN.
An SIS product referred to as RESTORE Orthobiologic Implant is available from DePuy Orthopaedics, Inc. in Warsaw, Ind. The DePuy product is described for use during rotator cuff surgery, and is provided as a resorbable framework that allows the rotator cuff tendon to regenerate itself. The RESTORE Implant is derived from porcine small intestine submucosa that has been cleaned, disinfected, and sterilized. Small intestine submucosa (SIS) has been described as a naturally-occurring ECM composed primarily of collagenous proteins. Other biological molecules, such as growth factors, glycosaminoglycans, etc., have also been identified in SIS. See Hodde et al., Tissue Eng. 2(3): 209-217 (1996); Voytik-Harbin et al., J. Cell Biochem., 67:478-491 (1997); McPherson and Badylak, Tissue Eng., 4(1): 75-83 (1998); Hodde et al., Endothelium, 8(1):11-24 (2001); Hodde and Hiles, Wounds, 13(5): 195-201 (2001); Hurst and Bonner, J. Biomater. Sci. Polym. Ed., 12(11) 1267-1279 (2001); Hodde et al., Biomaterial, 23(8): 1841-1848 (2002); and Hodde, Tissue Eng., 8(2): 295-308 (2002), all of which are incorporated by reference herein. During seven years of preclinical testing in animals, there were no incidences of infection transmission from the implant to the host, and the SIS material has not decreased the systemic activity of the immune system. See Allman et al., Transplant, 17(11): 1631-1640 (2001); Allman et al., Tissue Eng., 8(1): 53-62 (2002).
Other products made from porcine small intestine are commercially available. For example, Organogenesis, Inc., of Canton, Mass., is understood to market such products under the designations GRAFTPATCH, FORTAFLEX, FORTAGEN and FORTAPERM, and possibly under other designations.
While small intestine submucosa is available, other sources of submucosa are known to be effective for tissue remodeling. These sources include, but are not limited to, stomach, bladder, alimentary, respiratory, or genital submucosa, or liver basement membrane. See, e.g., U.S. Pat. Nos. 6,171,344, 6,099,567, and 5,554,389, hereby incorporated by reference. Further, while SIS is most often porcine derived, it is known that these various submucosa materials may be derived from non-porcine sources, including bovine and ovine sources. Additionally, other collageneous matrices are known, for example lamina propria and stratum compactum.
For the purposes of this disclosure, it is within the definition of a naturally occurring ECM to clean, delaminate, and/or comminute the ECM, or even to cross-link the collagen fibers within the ECM. It is also within the definition of naturally occurring ECM to fully or partially remove one or more sub-components of the naturally occurring ECM. However, it is not within the definition of a naturally occurring ECM to extract and purify the natural collagen or other components or sub-components of the ECM and reform a matrix material from the purified natural collagen or other components or sub-components of the ECM. Thus, while reference is made to SIS, it is understood that other naturally occurring ECMs are within the scope of this invention. Thus, in this application, the terms “naturally occurring extracellular matrix” or “naturally occurring ECM” are intended to refer to extracellular matrix material that has been cleaned, disinfected, sterilized, and optionally cross-linked. The terms “naturally occurring extracellular matrix” and “naturally occurring ECM” are also intended to include ECM foam material prepared as described in copending U.S. patent application Ser. No. 10/195,354 entitled “Porous Extracellular Matrix Scaffold and Method”, filed concurrently herewith.
The following patents, hereby incorporated by reference, disclose the use of ECMs for the regeneration and repair of various tissues: U.S. Pat. Nos. 6,334,872, 6,187,039, 6,176,880, 6,126,686, 6,099,567, 6,096,347, 5,997,575, 5,993,844, 5,968,096, 5,955,110, 5,922,028, 5,885,619, 5,788,625, 5,762,966, 5,755,791, 5,753,267, 5,733,337, 5,711,969, 5,645,860, 5,641,518, 5,554,389, 5,516,533, 5,460,962, 5,445,833, 5,372,821, 5,352,463, 5,281,422, and 5,275,826. U.S. Pat. Nos. 5,275,826 and 5,516,533 disclose providing a mass of SIS, particularly as a fluidized injectable mass, to promote repair of tissue defects. U.S. Pat. No. 5,352,463 discloses an SIS pillow filled with comminuted SIS for regeneration of a meniscus. While U.S. Pat. No. 5,352,463 contemplates the general concept of meniscus regeneration with an SIS filled pouch, it does not address itself to providing such a pouch having the capability of withstanding the compression and shear stresses involved in an implant for regenerating a meniscus.
The present disclosure relates to a device for regenerating a meniscus of a knee or a portion thereof. A natural meniscus in a human knee has a generally wedge-shaped cross-section, i.e., a section through a plane extending along and radially outwardly from the axis of the tibia either through the medial meniscus or the lateral meniscus will define a generally wedged-shaped cross-section. Typically, the device will be placed in a meniscal space from which a defective portion of the meniscus is removed, and that space will be a generally wedge-shaped space. The device will be placed in the space and anchored to the surrounding tissue. In one embodiment, a composite device will be inserted into the space from which the defective meniscus portion has been removed. The device comprises an upper cover made from toughened naturally occurring extracellular matrix (ECM), the cover defining a space therebelow. In some embodiments, the cover comprises a plurality of layers of naturally occurring ECM laminated together and toughened to withstand articulation stresses. A mass comprising comminuted naturally occurring ECM is disposed in the space. In various embodiments, the mass may also comprise bioactive agents, biologically-derived agents, cells, biological lubricants, biocompatible inorganic materials, biocompatible polymers and/or some combination thereof mixed with the comminuted ECM.
In some embodiments, a biocompatible polymer can be used in conjunction with naturally occurring ECM. See, for example, the teachings of U.S. patent application Ser. No. 10/195,341 entitled “Hybrid Biologic/Synthetic Porous Extracellular Matrix Scaffolds” filed contemporaneously herewith, and U.S. patent application Ser. No. 10/172,347 entitled “Hybrid Biologic-Synthetic Bioabsorbable Scaffolds,” which was filed on Jun. 14, 2002.
An implant for regeneration or repair of the meniscus of the knee may be toughened to withstand better the compression and/or shear forces of the knee for a sufficient amount of time for remodeling to begin. It will be understood that a surgeon may immobilize or partially immobilize the knee for a period of time subsequent to surgery. The rehabilitation protocol may include limited articulation, compression, and shear forces for a period of time. However, an implant that is toughened should be able to withstand even these reduced forces better than an equivalent implant that has not been toughened. At the same time, the material must be porous enough to permit remodeling. Thus, it is preferred that the condyle-facing surface of the ECM device of this disclosure is toughened to withstand the forces. Toughness may include stiffness (i.e. tensile modulus), resistance to delamination, increased thickness, resistance to shear or abrasion, decreased water content, or increased density, for example.
One method of toughening is dehydrothermal cross-linking. Techniques for dehydrothermal cross-linking are known in the art, but the steps in one method include applying mechanical pressure to the ECM while using vacuum to remove water, and subsequently delivering pressurized warm air to the ECM, thus producing a dehydrated ECM. Other methods of mechanical cross-linking, as are known in the art, may be used to toughen the upper cover of the device of the present disclosure. Such methods of physical cross-linking include, for example, freeze-drying, irradiation (ultraviolet or gamma irradiation) and combinations of methods. In addition, chemical cross-linking can be used to toughen the upper cover of the device of the present disclosure. Chemical cross-linking can be achieved through the use of materials like aldehydes, carbodiimides, glycation agents, enzymes and the like.
In some embodiments, the upper cover is formed by laminating a plurality of sheets of naturally occurring ECM and treating it to provide a toughened surface capable of withstanding the compression and shear stresses involved in knee articulation, i.e., the articulation of the knee condyle on the device inserted into the meniscus. The mass in the space below the upper cover may be comminuted SIS or is alternatively bioactive agents, biologically derived agents, cells or combinations thereof, for example. Other collageneous materials may also be used for the mass in the space below the upper cover, alone or in combination with the above-mentioned materials. The mass of comminuted naturally occurring ECM is believed to provide a framework for meniscus regeneration. The insertion of the device into the space from which the defective portion has been removed and the attachment of the device to the surrounding tissue places the device such that it is in contact with the host tissue of the remaining meniscus such that the meniscus will be regenerated in the space from which the defective portion is removed. However, in some embodiments the space below the upper cover is left empty; if desired, biological material may be implanted as a discrete element or could be injected intraoperatively or post-operatively for example.
To reduce the stress on the upper surface of the device, a lubricant may be affixed or applied to the toughened surface of the implant. For example, a lubricant such as hyaluronic acid may be affixed to the upper surface of the device by cross-linking. Other lubricants can also be used. Reference is made to U.S. patent application Ser. No. 10/195,606 entitled “Cartilage Repair and Regeneration Device and Method”, filed concurrently herewith, which is incorporated by reference herein in its entirety.
One embodiment, therefore, is a composite device comprising a cover of naturally occurring ECM and a framework therebelow provided to accommodate the regeneration. With the mass of comminuted ECM, the device serves as a cushion for the condyle load and a bearing surface for the condyle. By placing the device into close contact with the remaining portion of the meniscus, the regeneration will take place.
In another embodiment of the present invention, the device comprises a shell shaped conformingly to fit into the space occupied by the removed meniscus portion, the shell to provide an upper surface to withstand the articulation of the knee and a space below the upper surface. A bioactive agent, biologically derived agent, cells, biocompatible polymer, biocompatible inorganic material, biological lubricant or combinations thereof is disposed within the space. It will be appreciated that shells of different size and shape will be provided to surgeons such that they can remove a portion of the damaged meniscus conforming to the shape of a device to be inserted or size the shell to conform to the removed portion of damaged meniscus. Templates can be provided to guide the surgeon in the removal of the defective portion. Preferably, the device is shaped to conform to the space into which it is inserted such that the surrounding tissue of the remaining meniscus is in contact with the device. It has been found, for example, that a plug made from comminuted ECM such as SIS may be inserted into a hole in a meniscus to regenerate the meniscus and close the hole. Such a plug may be wrapped or covered with layers of SIS.
For handling purposes, the devices will preferably be made in a factory and supplied to the surgeons for selection and use based on size and shape. In some embodiments, the devices will be provided in dried or lyophilized condition to be hydrated by the surgeon. Portions of the exterior of the device, particularly those portions providing communication with the biological mass under the upper cover, may be perforated to expedite the hydration of the device.
In some embodiments, the device for regenerating a meniscus or a portion thereof comprises a wedge-shaped biological scaffold material body having an apex portion and a base portion spaced radially outwardly from the apex portion. The body provides an upper surface to face a condyle of the femur and to provide for articulation of the knee against the upper surface and a lower surface to face the tibial platform of the knee. This body, which may be fabricated from sheets or strips of naturally occurring ECM, is formed to provide a plurality of channels or compartments disposed between the upper and lower surfaces. In some embodiments, the channels or compartments extend radially inwardly from the base portion to the apex portion. In other embodiments, the channels or compartments extend circumferentially about the device, i.e., in the circumferential direction of the original meniscus. In some embodiments, the radially extending channels will be generally conical in shape with their large ends disposed toward the base portion and their smaller ends disposed toward the apex portion. In some embodiments, the circumferential channels will be arranged such that smaller diameter channels will be disposed toward the apex portion and larger diameter channels will be disposed adjacent the base portion.
These channels or compartments may be filled with comminuted naturally occurring ECMs to provide a framework for meniscus regeneration. In some embodiments, the comminuted ECM will be mixed with or replaced by bioactive agents, biologically-derived agents, cells, biological lubricants, biocompatible inorganic materials, biocompatible polymers and/or combinations thereof. The ECM material providing the upper surface and the lower surface may be laminated sheets or strips of an ECM material such as SIS which may be formed under pressure and heat. It will be appreciated that lyophilization may be used to dry the mass of comminuted material.
It will be appreciated that various structures may be provided within the concept of the present disclosure to produce a composite device having an upper cover made from a toughened sheet of a naturally occurring ECM with a mass of comminuted naturally occurring ECM therebelow to accommodate the regeneration of the meniscus. For example, a device for regenerating a meniscus or a portion thereof may comprise a wedge-shaped body having radially extending or circumferentially extending compartments or channels into which the comminuted ECM is placed. The upper or lower panels may merely serve as covers for the device's internal structure which may be made separately from the panels as will be further described herein. In some embodiments, the devices are made in the shape of a pillow, the upper and lower covers of which provide an interior space which is filled with a biological material to provide a framework for meniscus regeneration. Channels or compartments within the space between the upper and lower covers may be fabricated, for example, with partitions of ECM material to direct the regeneration. In some cases, the channels or compartments will extend radially inwardly and in other cases, the channels or compartments will extend circumferentially.
Various systems may be provided for forming naturally occurring ECMs such as SIS layers or strips to provide the panels or covers and to provide the recesses, channels or compartments in between the panels or covers. It has been found that layers of harvested and cleaned SIS may be drawn into cavities in vacuum forming operations. Such layers of SIS may be formed and then laminated together and dried by the application of heat and pressure. The mass of biological material such as the comminuted SIS may be placed in the vacuum formed cavities as part of the forming process.
The present invention also comprises a method of regenerating a portion of a knee meniscus comprising the steps of removing a segment of a meniscus to provide a partial meniscal space extending circumferentially about a predetermined portion of the tibial platform and leaving remaining segments of the original meniscus. This partial meniscal space will have a radially outer portion and a radially inner portion. The method involves providing an implant device constructed from naturally occurring ECMs and shaped to conform to the partial meniscal space. The device is placed into the space and then attached to the adjacent tissue of the knee. The method encourages regeneration from the radially outer portion of the device to the radially inner portion of the device. In embodiments of the present invention, the encouraging step comprises channeling blood flow from the vascular rich outer portion of the meniscus and the device to the radially inner portion of the device. The regeneration is encouraged by structuring the device such that the vascular rich portion of the original meniscus and the adjacent radially outer portion of the original meniscus will work with the device and particularly the mass of biological material under the upper cover of the device to regenerate the meniscal tissue.
In one embodiment, the method of the present invention, therefore, comprises the steps of replacing a portion of the original meniscus with a naturally occurring extracellular matrix material shaped and formed to provide an upper surface toughened to withstand the compression and shear stress of articulation of the knee and an interior space into which the meniscal regeneration occurs and attaching the material to the surrounding tissue to provide blood flow to the device. In some embodiments, the interior space is filled with a mass of comminuted naturally occurring extracellular matrix material, bioactive agents, biologically-derived agents, cells or various combinations thereof. In some embodiments, the comminuted ECM may be chemically cross-linked by chemical agents such as aldehydes, carbodiamide, glycation agents, enzymes or the like. See, for example, U.S. Pat. No. 6,042,610, already incorporated by reference, at columns 11-12. In some embodiments, the comminuted ECM may be physically cross-linked by heat (thermal cross-linking), radiation (ultraviolet or gamma irradiation), or combinations such as drying at elevated temperatures (dehydrothermal crosslinking). And in some embodiments a lubricating agent may be applied or affixed to the device.
For handling and installation purposes, some embodiments comprise a cover over a recess which is filled with biological materials and constructed to provide a framework for meniscus regeneration. At least the upper cover is formed from a material which will withstand the compression and shear stresses involved in articulation of the femur on the tibia, i.e., of the condyles on the tibia platform. It will be appreciated that this is a dynamic stress situation for the upper cover and, for that matter, for the device attached to the surrounding tissue or anchored in the space from which the defected meniscus portion is removed. This upper cover of the device may be provided by treating layers of ECM with heat and pressure to form a toughened upper surface.
In this specification and in the appended claims, unless expressly limited otherwise, it is intended that “toughened” or “treatment for toughening” shall involve treating ECM such as SIS with various treatment steps including such steps as laminating several layers of ECM strips together and treating the layers with compression and vacuum or heat or combinations of pressure, vacuum, and heat. It is contemplated that such layers may be laminated together and bonded by both mechanical compression and application of vacuum and/or heated air which accomplishes the bonding and also dries the product, leading to a dehydrated product. It has been found that several layers of SIS can be laminated together with heat, vacuum, and pressure to provide a portion of the composite structure. Illustratively, in some embodiments, both the upper cover and the lower cover defining the shell of the device are treated with heat and pressure to remove water from the ECM comprising the shell to produce a shell comprising a dehydrated naturally occurring extracellular matrix. It has been found that various drying conditions affect the toughness of the ECM. For example, changing the platen or drying surface in vacuum drying by reducing the size of the openings in the platen can increase the toughness of the resultant ECM. Drying in air or hot air, as compared to in vacuum, can also produce a dehydrated extracellular matrix having increased toughness. Any method to increase density, for example by increasing the number of layers of ECM in a given volume, will also increase toughness. Altering the orientation of layers, selecting older animals, selecting species having tougher ECMs, and processing techniques (for example, increasing concentration of peracetic acid or pressure from rollers) can also affect the toughness of the resultant ECM.
Unless otherwise expressly limited, “toughened” or “treatment for toughening” may also include other means of cross-linking ECM. As discussed above, the ECM can be chemically crosslinked to increase the toughness of all or a portion of the ECM through the use of agents such as aldehydes, carbodiimides, glycation agents, enzymes and the like. In addition, as discussed above, other methods of crosslinking the ECM may be used. For example, radiation (including UV, RF, and gamma radiation) could be used to toughen the ECM. When UV or RF radiation is used, preferably the ECM is crosslinked prior to final drying. Additionally, combinations of methods may be used, such as be drying at elevated temperatures (dehydrothermal crosslinking). All of such methods are intended to be included in the expressions “toughened” and “treatment for toughening” unless expressly limited.
In this specification and claims, unless expressly limited otherwise, “generally wedge-shaped” is intended to define the shape of a device that has a thick base portion and a thin apex portion, wherein the device tapers between the thick base portion and the thin apex portion. Although a generally wedge-shaped device can have flat upper and lower surfaces (see, e.g.,
In this specification and claims, unless otherwise expressly limited, “mass of biological material” is intended to include naturally occurring extracellular matrix, bioactive agents, and/or biologically-derived agents and cells. “Mass of biological material” is also intended to include biological materials formed in whole or in part from such matrices, agents and cells. Thus, “mass of biological material” includes comminuted extracellular matrix and extracellular matrix foams as disclosed in U.S. patent application Ser. No. 10/195,354 entitled “Porous Extracellular Matrix Scaffold and Method”, and hybrid materials, as disclosed in U.S. patent application Ser. No. 10/195,341 entitled “Hybrid Biologic/Synthetic Porous Extracellular Matrix Scaffolds”, all of which are filed concurrently herewith, and U.S. patent application Ser. No. 10/172,347 entitled “Hybrid Biologic-Synthetic Bioabsorbable Scaffolds” which was filed on Jun. 14, 2002, the disclosures of which are incorporated by reference herein. Unless otherwise expressly limited, “mass of biological material” includes material from which commercially available products are made, including, for example: the RESTORE® Orthobiologic Implant, available from DePuy Orthopaedics, Inc. of Warsaw, Indiana; OASIS and SURGISIS products available from Cook Biotech, Inc. of Bloomington, Indiana; “TISSUEMEND” available from TEI Biosciences Inc. of Boston, Mass.; and GRAFTPATCH, FORTAFLEX, FORTAGEN and FORTAPERM products available from Organogenesis, Inc. of Canton, Mass. Unless expressly limited otherwise, the expression “mass of biological material” is also intended to encompass purified collagen, such as that disclosed in U.S. Pat. No. 6,042,610. The expression “mass of biological material” is intended to encompass all such materials regardless of whether they include another material, regardless of their physical state (e.g. powder or foam), and regardless of whether they are cross-linked or otherwise toughened, unless otherwise expressly stated. The expression “mass of biological material” should be understood to encompass both materials that are integral and that which comprise discrete elements. “Mass of biological material” should also be understood to encompass all forms of these materials, including dry forms, solutions, dispersions, gels, and pastes for example. Specific examples of materials for the mass of biological materials include: comminuted ECM; ECM pieces; ECM foam; an ECM roll; woven ECM; a non-woven ECM mat; braided ECM; ECM solution; ECM dispersion; ECM slurry; ECM gel; ECM paste; and ECM that has not been toughened. Such ECMs include but are not limited to: comminuted SIS; SIS pieces; SIS foam; an SIS roll; woven SIS; non-woven SIS mat; braided SIS; SIS solution; SIS dispersion; SIS slurry; SIS gel; SIS paste; and SIS that has not been toughened.
In the specification and claims, “comminuted” is intended to mean reduced to pieces. “Piece” and “pieces” are intended to mean any fiber, strip, ribbon, sliver, filament, shred, bit, fragment, part, flake, slice, cut, chunk, or other portion of solid or solid-like material. “Comminuted” is not intended to imply any particular means of producing the pieces. No particular shape is intended to be implied by the use of the word “comminuted” unless otherwise expressly limited; the pieces can comprise a variety of two and three dimensional shapes of material. Moreover, unless a specific size of material is specified, the use of the term “comminuted” is not intended to imply any particular size of pieces.
“Bioactive agents” include one or more of the following: chemotactic agents; therapeutic agents (e.g. antibiotics, steroidal and non-steroidal analgesics and anti-inflammatories, anti-rejection agents such as immunosuppressants and anti-cancer drugs); various proteins (e.g. short chain peptides, bone morphogenic proteins, glycoprotein and lipoprotein); cell attachment mediators; biologically active ligands; integrin binding sequence; ligands; various growth and/or differentiation agents (e.g. epidermal growth factor, IGF-I, IGF-II, TGF-β I-III, growth and differentiation factors, vascular endothelial growth factors, fibroblast growth factors, platelet derived growth factors, insulin derived growth factor and transforming growth factors, parathyroid hormone, parathyroid hormone related peptide, bFGF; TGF62 superfamily factors; BMP-2; BMP-4; BMP-6; BMP-12; sonic hedgehog; GDF5; GDF6; GDF8; PDGF); small molecules that affect the upregulation of specific growth factors; tenascin-C; hyaluronic acid; chondroitin sulfate; fibronectin; decorin; thromboelastin; thrombin-derived peptides; heparin-binding domains; heparin; heparan sulfate; DNA fragments and DNA plasmids. If other such substances have therapeutic value in the orthopaedic field, it is anticipated that at least some of these substances will have use in the present invention, and such substances should be included in the meaning of “bioactive agent” and “bioactive agents” unless expressly limited otherwise.
“Biologically derived agents” include one or more of the following: bone (autograft, allograft, and xenograft) and derivates of bone; cartilage (autograft, allograft, and xenograft), including, for example, meniscal tissue, and derivatives; ligament (autograft, allograft, and xenograft) and derivatives; derivatives of intestinal tissue (autograft, allograft, and xenograft), including for example submucosa; derivatives of stomach tissue (autograft, allograft, and xenograft), including for example submucosa; derivatives of bladder tissue (autograft, allograft, and xenograft), including for example submucosa; derivatives of alimentary tissue (autograft, allograft, and xenograft), including for example submucosa; derivatives of respiratory tissue (autograft, allograft, and xenograft), including for example submucosa; derivatives of genital tissue (autograft, allograft, and xenograft), including for example submucosa; derivatives of liver tissue (autograft, allograft, and xenograft), including for example liver basement membrane; derivatives of skin (autograft, allograft, and xenograft); platelet rich plasma (PRP), platelet poor plasma, bone marrow aspirate, demineralized bone matrix, insulin derived growth factor, whole blood, fibrin and blood clot. Purified ECM and other collagen sources are also intended to be included within “biologically derived agents.” If other such substances have therapeutic value in the orthopaedic field, it is anticipated that at least some of these substances will have use in the present invention, and such substances should be included in the meaning of “biologically-derived agent” and “biologically-derived agents” unless expressly limited otherwise.
“Biologically derived agents” also include bioremodelable collageneous tissue matrices. The expressions “bioremodelable collagenous tissue matrix” and “naturally occurring bioremodelable collageneous tissue matrix” include matrices derived from native tissue selected from the group consisting of skin, artery, vein, pericardium, heart valve, dura mater, ligament, bone, cartilage, bladder, liver, stomach, fascia and intestine, tendon, whatever the source. Although “naturally occurring bioremodelable collageneous tissue matrix” is intended to refer to matrix material that has been cleaned, processed, sterilized, and optionally crosslinked, it is not within the definition of a naturally occurring bioremodelable collageneous tissue matrix to purify the natural fibers and reform a matrix material from purified natural fibers. The term “bioremodelable collageneous tissue matrices” includes “extracellular matrices” within its definition.
“Cells” include one or more of the following: chondrocytes; fibrochondrocytes; osteocytes; osteoblasts; osteoclasts; synoviocytes; bone marrow cells; mesenchymal cells; stromal cells; stem cells; embryonic stem cells; precursor cells derived from adipose tissue; peripheral blood progenitor cells; stem cells isolated from adult tissue; genetically transformed cells; a combination of chondrocytes and other cells; a combination of osteocytes and other cells; a combination of synoviocytes and other cells; a combination of bone marrow cells and other cells; a combination of mesenchymal cells and other cells; a combination of stromal cells and other cells; a combination of stem cells and other cells; a combination of embryonic stem cells and other cells; a combination of precursor cells isolated from adult tissue and other cells; a combination of peripheral blood progenitor cells and other cells; a combination of stem cells isolated from adult tissue and other cells; and a combination of genetically transformed cells and other cells. If other cells are found to have therapeutic value in the orthopaedic field, it is anticipated that at least some of these cells will have use in the present invention, and such cells should be included within the meaning of “cell” and “cells” unless expressly limited otherwise. Illustratively, in one example of embodiments that are to be seeded with living cells such as chondrocytes, a sterilized implant may be subsequently seeded with living cells and packaged in an appropriate medium for the cell type used. For example, a cell culture medium comprising Dulbecco's Modified Eagles Medium (DMEM) can be used with standard additives such as non-essential amino acids, glucose, ascorbic acid, sodium pyruvate, fungicides, antibiotics, etc., in concentrations deemed appropriate for cell type, shipping conditions, etc.
“Biological lubricants” include: hyaluronic acid and its salts, such as sodium hyaluronate; glycosaminoglycans such as dermatan sulfate, heparan sulfate, chondroiton sulfate and keratan sulfate; synovial fluid and components of synovial fluid, including as mucinous glycoproteins (e.g. lubricin), tribonectins, articular cartilage superficial zone proteins, surface-active phospholipids, lubricating glycoproteins I, II; vitronectin, and rooster comb hyaluronate. “Biological lubricant” is also intended to include commercial products such as ARTHREASE™ high molecular weight sodium hyaluronate, available in Europe from DePuy International, Ltd. of Leeds, England, and manufactured by Bio-Technology General (Israel) Ltd., of Rehovot, Israel; SYNVISC® Hylan G-F 20, manufactured by Biomatrix, Inc., of Ridgefield, N.J. and distributed by Wyeth-Ayerst Pharmaceuticals of Philadelphia, Pa.; HYLAGAN® sodium hyaluronate, available from Sanofi-Synthelabo, Inc., of New York, N.Y., manufactured by FIDIA S.p.A., of Padua, Italy; and HEALON® sodium hyaluronate, available from Pharmacia Corporation of Peapack, N.J. in concentrations of 1%, 1.4% and 2.3% (for opthalmologic uses). If other such substances have therapeutic value in the orthopaedic field, it is anticipated that at least some of these substances will have use in the present invention, and such substances should be included in the meaning of “biological lubricant” and “biological lubricants” unless expressly limited otherwise.
“Biocompatible polymers” is intended to include both synthetic polymers and biopolymers (e.g. collagen). Examples of biocompatible polymers include: polyesters of [alpha]-hydroxycarboxylic acids, such as poly(L-lactide) (PLLA) and polyglycolide (PGA); poly-p-dioxanone (PDS); polycaprolactone (PCL); polyvinyl alcohol (PVA); polyethylene oxide (PEO); polymers disclosed in U.S. Pat. Nos. 6,333,029 and 6,355,699; and any other bioresorbable and biocompatible polymer, co-polymer or mixture of polymers or co-polymers that are utilized in the construction of prosthetic implants. In addition, as new biocompatible, bioresorbable materials are developed, it is expected that at least some of them will be useful materials from which portions of the devices may be made. It should be understood that the above materials are identified by way of example only, and the present disclosure is not limited to any particular material unless expressly called for in the claims.
“Biocompatible inorganic materials” include materials such as hydroxyapatite, all calcium phosphates, alpha-tricalcium phosphate, beta-tricalcium phosphate, calcium carbonate, barium carbonate, calcium sulfate, barium sulfate, polymorphs of calcium phosphates, sintered and non-sintered ceramic particles and combinations of such materials. If other such substances have therapeutic value in the orthopaedic field, it is anticipated that at least some of these substances will have use in the present invention, and such substances should be included in the meaning of “biocompatible inorganic material” and “biocompatible inorganic materials” unless expressly limited otherwise.
It is expected that various combinations of bioactive agents, biologically derived agents, cells, biological lubricants, biocompatible inorganic materials, biocompatible polymers can be used with the scaffolds of the present invention. Various techniques may be used to fix the devices of the present invention. Examples of suitable devices and methods are disclosed in U.S. Patent Application “Unitary Surgical Device and Method”, filed concurrently herewith and incorporated by reference herein in its entirety. Reference is also made to the following applications for filed concurrently herewith and incorporated by reference herein: U.S. patent application Ser. No. 10/195,719 entitled “Devices from Naturally Occurring Biologically Derived Materials”; and U.S. Patent Application Serial No. “Cartilage Repair Apparatus and Method”). To facilitate fixation of the devices to surrounding tissue, the lower cover or the upper cover may be extended. In some cases, the extension of the lower cover or upper cover will be provided with tacks to facilitate the attachment of the device to surrounding tissues. One or more of the layers of the material forming the upper cover or the lower cover may be formed to provide tabs extending away from the device to facilitate attachment of the device to the surrounding tissue.
A repair device may be made in accordance with the present invention in a form such that it can be pulled into, or otherwise placed within, the faces of a tear in a meniscus to extend along the tear. The device comprises strips of naturally occurring ECM material laminated together to form a body portion and at least one extension portion extending away from the body portion. The body portion is shaped to be pulled by the extension portion into the tear to extend along and fill the tear. This body portion may comprise a mass of comminuted naturally occurring ECM captured between the strips to serve as a framework for closing or regenerating the tear. The body portion may be divided into a series of compartments which may be pulled into a tear with a space between each compartment such that the surgeon may trim the device between the compartments.
Thus, one aspect of this disclosure is a device for regenerating a meniscus or a portion thereof, the device comprising a wedge-shaped body having an upper panel and a lower panel angularly separated to define an apex portion and a base portion, the panels being formed of a naturally occurring extracellular matrix.
Another aspect of this disclosure is a device for regenerating a knee meniscus or a portion thereof, the device comprising a wedge-shaped body formed from a naturally occurring extracellular matrix having an apex portion and a base portion spaced radially outwardly from the apex portion, the body providing an upper surface to face a condyle of a femur of the knee and provide an articulation surface therefor and a lower surface to face a tibial platform of the knee, the body providing a plurality of channels disposed between the upper and lower surfaces.
Yet another aspect of this disclosure is a device for regenerating a meniscus of a knee or a portion thereof, the device comprising a shell made from a toughened naturally occurring extracellular matrix and a biologic material to provide a framework for meniscus regeneration disposed in the shell.
Still another aspect of this disclosure is a device for regenerating the meniscus of a knee or a part thereof, the device comprising a plurality of layers of naturally occurring extracellular matrix material laminated together and formed in the shape of a meniscus with an outer radial portion, an inner radial portion and opposite end portions, one or more of the layers being formed to provide a plurality of tabs extending away from the device to be attached to the surrounding tissue of the knee to attach the device.
A further aspect of this disclosure is an implant for regenerating a meniscus or portions of a meniscus on a tibial platform to serve as a support bearing for a condyle above the platform, the implant comprising an outer cover formed from sheets of a naturally occurring extracellular matrix material layered together and formed and toughened by dehydrothermal cross-linking to provide a bearing surface to withstand the forces generated by articulation of the condyle relative to the platform and a biological material below the cover to provide a framework for regenerating the meniscus.
Another aspect of this disclosure is an implant for regenerating a portion of a meniscus in the knee, the implant comprising an outer cover providing a cavity, an upper surface to face the femur of the knee and a lower surface to face the tibial platform of the knee, the cavity being disposed between the surfaces of the cover, the outer cover being formed from a material selected from the group consisting of SIS, stomach submucosa, bladder submucosa, alimentary submucosa, respiratory submucosa, genital submucosa, and liver basement membrane, the upper surface being toughened by cross-linking the collagen fibers, and the cavity being filled with a material selected from the group consisting of blood clots, fibrin, comminuted ECMs and PRP.
An additional aspect of this disclosure is an implant for regenerating a portion of a meniscus in a knee, the implant having a radially outer portion, a radially inner portion, an upper surface and a lower surface, the outer and inner portions being curved to conform to the outer and inner portions, respectively, of the portion of the meniscus to be regenerated, the implant having an outer shell defining the outer and inner portions and upper and lower surfaces, the outer shell being formed from naturally occurring extracellular matrix material, and at least the upper surface being toughened, the shell having a space therein, and a biological material disposed in the space to provide a framework for regenerating the meniscus.
A further aspect of this disclosure is an implant for regenerating a knee meniscus or a portion thereof, the implant having radially outer and inner portions corresponding to the radially outer and inner portions of the portion of the meniscus to be regenerated, and an outer shell providing an inner space extending from the outer portion to the inner portion, the outer shell having an upper surface to be engaged by the femur of the knee and a lower surface to be supported on the tibial platform of the knee, the outer shell being formed from a plurality of layers of SIS laminated together and treated to be toughened to withstand the shearing and compressive forces in the knee in vivo, and at least one material selected from the group consisting of fibrin, blood clots, comminuted SIS and PRP disposed in the space to accommodate the meniscus regeneration.
In another aspect of this disclosure a method is provided for regenerating a portion of a knee meniscus having a radially outer portion and a radially inner portion, the meniscus portion extending circumferentially about a medial or a lateral portion of the tibial platform of the knee, the method comprising the steps of: removing a segment of a meniscus to provide a meniscal space extending circumferentially about a predetermined portion of the tibial platform and leaving remaining segments of the original meniscus, the meniscal space having a radially outer portion and a radially inner portion, providing an implant device constructed from a naturally occurring extracellular matrix to conform to the meniscal space and placing the device into the space, the device having a radially outer portion and a radially inner portion, attaching the device to the adjacent tissue of the knee, and encouraging in regeneration from the radially outer portion of the device to the radially inner portion of the device.
In yet another aspect of this disclosure a method is provided for regenerating a meniscus or a portion thereof comprising the steps of: replacing a portion of an original meniscus with a naturally occurring extracellular matrix material shaped to conform to the meniscus portion removed, and shaping the material such that in vivo the material defines channels extending from the radially outer portion of the meniscus to the radially inner portion of the meniscus to support the regeneration.
In a further aspect of this disclosure a method is provided for regenerating a knee meniscus or a portion thereof comprising the steps of: replacing a portion of an original meniscus with a naturally occurring extracellular matrix material shaped and formed to provide an upper surface toughened to withstand the compression and shear stress of articulation of the knee and an interior space into which meniscal regeneration occurs, and attaching the material to the surrounding tissue.
Still another aspect of this disclosure is a device for regenerating a removed portion of a knee meniscus, the device comprising a shell shaped conformingly to fit into the space occupied by the removed meniscus portion, the shell providing an upper surface to withstand the articulation of the knee and a space under the upper surface, and a biologically derived agent, said biologically derived agent comprising a material selected from the group consisting of comminuted naturally occurring extracellular matrix, fibrin, blood clot and platelet rich plasma (PRP) disposed within the space.
Yet another aspect of this disclosure is a composite device for insertion into a space in a knee meniscus from which space a meniscus portion has been removed, the device comprising an upper cover made from a toughened sheet of naturally occurring extracellular matrix (ECM), the cover defining therebelow a space, and a mass comprising comminuted naturally occurring ECM disposed in the space.
Still another aspect of this disclosure is a plug to be inserted into an opening formed in a knee meniscus, the plug comprising a mass of comminuted naturally occurring ECM formed into the shape of a plug.
A further aspect of this disclosure is a device for repairing a tear in a knee meniscus, the device comprising strips of naturally occurring extracellular matrix laminated together to form a body portion and at least one extension portion extending away from the body portion, the body portion being shaped to be pulled by the extension portion into the tear to extend along and fill the tear.
Moreover, an additional aspect of this disclosure is a device for regenerating a meniscus or a portion thereof, the device comprising a wedge-shaped body having an upper panel and a lower panel angularly separated to define an apex portion and a base portion, the panels being formed of a naturally occurring extracellular matrix, and a support structure disposed between the upper panel and lower panel, the support structure comprising one or more members of rigid and hardened naturally occurring extracellular matrix.
One more aspect of this disclosure is an implantable device for repairing or regenerating at least a portion of a meniscus of a knee, the device comprising a toughened laminate including layers of ECM, the layers of ECM being toughened by a method selected from the group consisting of: compressing the layers of ECM together with heat to form the toughened laminate; compressing the layers of ECM together with vacuum to form the toughened laminate; compressing the layers of ECM together with pressure to form the toughened laminate; mechanically pressing the layers of ECM together while heating the layers to form the toughened laminate; and cross-linking the ECM laminate.
Still another aspect of this disclosure is an implantable device for repairing or regenerating at least a portion of a meniscus of a knee, the device comprising a toughened outer surface and a mass of biological material to provide a framework for meniscus regeneration, at least part of the mass of biological material being covered by the toughened outer surface.
Yet another aspect of this disclosure is an implantable device for repairing or regenerating at least a portion of a meniscus of a knee, the device comprising a wedge-shaped body having an upper panel and a lower panel angularly separated to define an apex portion and a base portion, at least part of the device comprising naturally occurring ECM.
In an additional aspect of this disclosure an implantable device is provided for regenerating at least a portion of a meniscus of a knee, the device comprising a cover sheet and a mass of biological material, the cover sheet extending over and beyond the mass of biological material.
Yet another aspect of this disclosure is an implantable device for regenerating at least a portion of a meniscus of a knee, the device comprising a plurality of surfaces defining compartments, a mass of biological material in each compartment, and a cover extending over the compartments and masses of biological material.
Still another aspect of this disclosure is an implantable device for regenerating at least a portion of a meniscus of a knee, the device comprising at least two adjacent materials having different densities, wherein each of the materials comprises ECM, wherein at least one of the material is treated to increase its density.
An additional aspect of this disclosure is an implantable device for repairing or regenerating at least a portion of vertebrate tissue, the device comprising a sheet of naturally occurring ECM having a density of at least 0.9 gm/cm3.
One more aspect of this disclosure is an implantable device for repairing or regenerating at least a portion of a meniscus of a knee, the device comprising a toughened laminate including layers of naturally occurring bioremodelable collageneous matrix, the laminate being toughened by a method selected from the group consisting of: compressing the layers of naturally occurring bioremodelable collageneous matrix together with heat to form the toughened laminate; compressing the layers of naturally occurring bioremodelable collageneous matrix together with vacuum to form the toughened laminate; compressing the layers of naturally occurring bioremodelable collageneous matrix together with pressure to form the toughened laminate; mechanically pressing the layers of naturally occurring bioremodelable collageneous matrix together while heating the layers to form the toughened laminate; and cross-linking the naturally occurring bioremodelable collageneous matrix laminate.
A final aspect of this disclosure is an implantable device for repairing or regenerating at least a portion of vertebrate tissue, the device comprising a sheet of naturally occurring bioremodelable collageneous matrix toughened to have a density of at least 0.9 gm/cm3.
The above and other features of the present disclosure will become apparent from the following description and the attached drawings.
In the drawings:
a) shows a plurality of mandrels about which SIS is wrapped to form a plurality of channels;
a) shows an illustrative method for forming several cylindrical channels together.
b) shows the device of
a) (b) and (c) show the process started in
a shows a further step in the process started in
Referring to
The portion 14 removed from the structure shown in
Turning to
Subsequently, to toughen one or more of the surfaces of device 80, either or both of pumps 54 and 72 may be replaced with compressors to provide pressurized hot air to laminated layers 58 and/or 64, in combination with the mechanical pressure. The pressurized air is typically provided at room temperature to 120° C., and more typically from 30 to 70° C. Thus, it is understood that elements 54 and 72 in the drawings represent sources of vacuum and pressurized air. The combination of mechanical pressure and hot air results in toughened layers through dehydrothermal cross-linking.
As a result of toughening the ECM layers as described above, with heat and compression, the resultant toughened ECM laminate can be expected to be more dense than standard commercial ECM products. As an example, a toughened SIS laminate formed from twenty (20) layers of SIS material compressed in a vacuum bed at a temperature of 30° C. for 1 hour was determined to have a density of about 0.933+/−0.061 g/cm3. It can be expected that the density and other properties of such toughened ECM laminates can be varied with variations in processing conditions such as temperature and pressure. In comparison, the commercially available RESTORE® SIS laminate product has a density of 0.466+/−0.074 gm/cm3. A hardened SIS device as described in U.S. Provisional patent application Ser. No. 10/195,719 entitled “Devices from Naturally Occurring Biologically Derived Materials”, filed concurrently herewith, can be made with a density of 0.747+/−0.059 gm/cm3, for example. An SIS foam can be made as described in U.S. patent application Ser. No. 10/195,354 entitled “Porous Extracellular Matrix Scaffold and Method”, filed concurrently herewith, with a substantially lower density: 0.091+/−0.019 gm/cm3; 0.035+/−0.012 μm/cm3; or 0.006+/−0.002 gm/cm3, for example.
While the
The sequence of the system of
As discussed above, a naturally occurring ECM for use in this invention is SIS. While SIS is commercially available, an illustrative method of obtaining SIS is as follows. Porcine SIS preferably comes from pigs raised on a Specific Pathogen Free farm. Such pigs are free from all pneumonia, diarrhea, lice, mange, and dysentery. The average pig weight is 220-280 lbs. The age of each pig should be between 150-200 days, and each pig is free from antibiotic administration for 21 days before slaughter. It is preferable that no unrefined animal byproducts be included in the pigs' diets. The SIS is obtained from the slaughterhouse by standard methods of obtaining casings. However, unless the SIS is used immediately, it is preferred that the SIS be stored in a frozen state lower than −20° C., and most preferably at −80° C. The SIS may be cleaned and disinfected by standard techniques, for example with 20% ethanol and 0.15% peracetic acid.
The device formed under pressure, compression, and heat in the system shown in
Laminating the layers 64 under heat and pressure will provide a toughened surface to serve as a bearing surface against which a condyle will move. Ultimately, after insertion into the knee, and over a period of time, the device 80 will be remodeled to regenerate the damaged portion of the meniscus. Illustratively, subsequent to insertion, the patient will recuperate for 3-6 weeks without substantial load bearing on the knee. During this time, body fluids such as blood and synovial fluids infuse into the implant. If additional biological lubricants such as hyaluronic acid are injected into the site, such injected fluids also infuse into the implant. Other lubricants could also be used in addition to or alternatively from hyaluronic acid: lubricin, articular cartilage surface zone proteins, synovial fluid, surface-active phospholipids, and lubricating glycoprotein I, II, or any combination thereof, for example. The cells that infuse into the implant are known to proliferate in mass 60. Subsequently, when the patient resumes load bearing on the knee, it is believed that the cells begin secreting structural proteins (mostly collagens) in response to exposure to the forces of load bearing. These secreted structural proteins reform the meniscal body. It is believed that layers 64 eventually abrade away due to mechanical shearing or due to bioabsorption.
The device 80, therefore, is a composite device comprising layers of naturally occurring ECM material treated to provide a bearing surface and additional ECM material positioned below that surface to provide a framework into which regeneration of the meniscus occurs.
It will be appreciated that tacks 130 may be made from well known materials that dissolve or absorb over time in the body. Such materials include, but are not limited to, PLA, PGA, a PLA-PGA copolymer, etc. In addition, as disclosed in U.S. Patent Application “Unitary Surgical Device and Method” application Ser. No. 10/483,929, filed concurrently and incorporated by reference herein, ECM can also be used for fixating elements like tacks 130.
Furthermore, the device 160 shown in
Turning to the diagrammatic views
The device 180 may be trimmed as indicated by the lines 220 as shown in
Alternatively, device 230 may be formed by wrapping successive mandrels together, similar to the method illustrated in
As shown in
The device 230 may be perforated as discussed above at some point in the processing to facilitate hydration before implantation in surgery. Particularly, the lower cover and the compartments of the device may be perforated to facilitate hydration.
The device 300 may be provided with attachment tacks as indicated at 312 and the lower cover of the device and the sides and base end of the device may be perforated as indicated at 314 to expedite the hydration before implantation in surgery. The surgeon may trim the device 300 along the lines indicated at 316 to provide the required fit.
As shown in
The device illustrated in
While in the various embodiments discussed herein, tacks and sutures have been shown for anchoring the devices, it will be appreciated that the devices may be anchored by sutures or any other method at the choice of the surgeon. Examples of alternative methods of anchoring the devices are illustrated and described in U.S. patent application “Unitary Surgical Device and Method” application Ser. No. 10/483,929, filed contemporaneously herewith and incorporated by reference herein.
The central body portion of the device 330 may be a pouch or somewhat pillow-like device with a generally wedge-shaped cross-section filled with comminuted ECMs as discussed above. It is contemplated that the device 330 will be placed in the space from which a defective portion of a meniscus is excised as illustrated in
In the embodiments illustrated in
Illustratively, the device 360 may be shaped and formed as diagrammatically illustrated in
a), 44(b) and 44(c) show the progression of the insertion of the device 360 into the tear 393. A surgeon may cut away a portion of the device 360 which extends above the upper surface of the meniscus as suggested in
It should be appreciated that in the embodiments illustrated in
Referring to
Thus, with the assembly of members 500 gathered together on the sutures 504 and inserted into the cover (panels 510, 512) and filled with the material 522, the device 506 may be inserted into an opening 516 cut into the meniscus and held to the meniscus with the suture 504 as suggested in
It should be appreciated that the ECM material described above may in some embodiments be combined with other materials. For example, the ECM material can be combined with a biocompatible polymer. Considering
Although the invention has been described with reference to a device for regenerating a meniscus or portion of a meniscus, it should be understood that the principles of the invention can also be applied to produce devices for regenerating other intra-articular cartilage. For example, the principles of the invention can be applied to produce devices that are useful in regenerating other fibrocartilage, such as that present in the temporomandibular joint and between vertebrae. The principles of the invention may also be applied to produce devices for use in repair and regeneration of articular hyaline cartilage.
There are a plurality of advantages of the present disclosure arising from the various features of the apparatus and methods described herein. It will be noted that alternative embodiments of the apparatus and methods of the present disclosure may not include all of the features described yet still benefit from at least some of the advantages of such features. Those of ordinary skill in the art may readily devise their own implementations of an apparatus and method that incorporate one or more of the features of the present disclosure and fall within the spirit and scope of the present disclosure.
This application claims the benefit of U.S. Provisional Application Nos. 60/388,713, filed Jun. 14, 2002, and 60/305,786, filed on Jul. 16, 2001, which are incorporated by reference herein in there entirety. Cross reference is made to U.S. patent application Ser. No. 10/195,719 entitled “Devices from Naturally Occurring Biologically Derived Materials”; Ser. No. 10/195,347 entitled “Cartilage Repair Apparatus and Method”; Ser. No. 10/195,344 entitled “Unitary Surgical Device and Method”; Ser. No. 10/195,341 entitled “Hybrid Biologic/Synthetic Porous Extracellular Matrix Scaffolds”; Ser. No. 10/195,606 entitled “Cartilage Repair and Regeneration Device and Method”; Ser. No. 10/195,354 entitled “Porous Extracellular Matrix Scaffold and Method”; Ser. No. 10/195,334 entitled “Cartilage Repair and Regeneration Scaffolds and Method”; and Ser. No. 10/195,633 entitled “Porous Delivery Scaffold and Method”, each of which is assigned to the same assignee as the present application, each of which is filed concurrently herewith, and each of which is hereby incorporated by reference. Cross reference is also made to U.S. patent application Ser. No. 10/172,347 entitled “Hybrid Biologic-Synthetic Bioabsorbable Scaffolds” which was filed on Jun. 14, 2002, which is assigned to the same assignee as the present application, and which is hereby incorporated by reference.
Number | Name | Date | Kind |
---|---|---|---|
3272204 | Artandi et al. | Sep 1966 | A |
3562820 | Braun | Feb 1971 | A |
4105034 | Shalaby et al. | Aug 1978 | A |
4130639 | Shalaby et al. | Dec 1978 | A |
4140678 | Shalaby et al. | Feb 1979 | A |
4141087 | Shalaby et al. | Feb 1979 | A |
4205399 | Shalaby et al. | Jun 1980 | A |
4208511 | Shalaby et al. | Jun 1980 | A |
4352463 | Baker | Oct 1982 | A |
4400833 | Kurland | Aug 1983 | A |
4418691 | Yannas et al. | Dec 1983 | A |
4610397 | Fischer et al. | Sep 1986 | A |
4642120 | Nevo et al. | Feb 1987 | A |
4669473 | Richards et al. | Jun 1987 | A |
4703108 | Silver et al. | Oct 1987 | A |
4705040 | Mueller et al. | Nov 1987 | A |
4741330 | Hayhurst | May 1988 | A |
4750492 | Jacobs | Jun 1988 | A |
4775361 | Jacques et al. | Oct 1988 | A |
4846835 | Grande | Jul 1989 | A |
4873976 | Schreiber | Oct 1989 | A |
4880429 | Stone | Nov 1989 | A |
4902508 | Badylak et al. | Feb 1990 | A |
4917084 | Sinofsky | Apr 1990 | A |
4919667 | Richmond | Apr 1990 | A |
4956178 | Badylak et al. | Sep 1990 | A |
4956179 | Bamberg et al. | Sep 1990 | A |
4976715 | Bays et al. | Dec 1990 | A |
5007934 | Stone | Apr 1991 | A |
5013323 | Kobayashi et al. | May 1991 | A |
5061286 | Lyle | Oct 1991 | A |
5102421 | Anspach, Jr. | Apr 1992 | A |
5108438 | Stone | Apr 1992 | A |
5116374 | Stone | May 1992 | A |
5128326 | Balazs et al. | Jul 1992 | A |
RE34021 | Mueller et al. | Aug 1992 | E |
5227627 | Gamarnik et al. | Jul 1993 | A |
5236431 | Gogolewski et al. | Aug 1993 | A |
5246441 | Ross et al. | Sep 1993 | A |
5258015 | Li et al. | Nov 1993 | A |
5269809 | Hayhurst et al. | Dec 1993 | A |
5275826 | Badylak et al. | Jan 1994 | A |
5281422 | Badylak et al. | Jan 1994 | A |
5306311 | Stone et al. | Apr 1994 | A |
5320633 | Allen et al. | Jun 1994 | A |
5329846 | Bonutti | Jul 1994 | A |
5341292 | Zamenhof | Aug 1994 | A |
5350583 | Yoshizato et al. | Sep 1994 | A |
5352463 | Badylak et al. | Oct 1994 | A |
5372821 | Badylak et al. | Dec 1994 | A |
5374268 | Sander | Dec 1994 | A |
5376118 | Kaplan et al. | Dec 1994 | A |
5380334 | Torrier et al. | Jan 1995 | A |
5445833 | Badylak et al. | Aug 1995 | A |
5447940 | Harvey et al. | Sep 1995 | A |
5460962 | Kemp | Oct 1995 | A |
5464929 | Bezwada et al. | Nov 1995 | A |
5479033 | Baca et al. | Dec 1995 | A |
5514181 | Light et al. | May 1996 | A |
5516533 | Badylak et al. | May 1996 | A |
5520691 | Branch | May 1996 | A |
5545178 | Kensey et al. | Aug 1996 | A |
5554389 | Badylak et al. | Sep 1996 | A |
5569252 | Justin et al. | Oct 1996 | A |
5573784 | Badylak et al. | Nov 1996 | A |
5591234 | Kirsch | Jan 1997 | A |
5593441 | Lichtenstein et al. | Jan 1997 | A |
5595621 | Light et al. | Jan 1997 | A |
5595751 | Bezwada et al. | Jan 1997 | A |
5597579 | Bezwada et al. | Jan 1997 | A |
5601558 | Torrie et al. | Feb 1997 | A |
5607687 | Bezwada et al. | Mar 1997 | A |
5618552 | Bezwada et al. | Apr 1997 | A |
5620698 | Bezwada et al. | Apr 1997 | A |
5626614 | Hart | May 1997 | A |
5630824 | Hart | May 1997 | A |
5632745 | Schwartz | May 1997 | A |
5641518 | Badylak et al. | Jun 1997 | A |
5645850 | Bezwada et al. | Jul 1997 | A |
5645860 | Knapp, Jr. et al. | Jul 1997 | A |
5648088 | Bezwada et al. | Jul 1997 | A |
5660225 | Saffran | Aug 1997 | A |
5668288 | Storey et al. | Sep 1997 | A |
5669912 | Spetzler | Sep 1997 | A |
5677355 | Shalaby et al. | Oct 1997 | A |
5681353 | Li et al. | Oct 1997 | A |
5693085 | Buirge et al. | Dec 1997 | A |
5695998 | Badylak et al. | Dec 1997 | A |
5698213 | Jamiolkowski et al. | Dec 1997 | A |
5700583 | Jamiolkowski et al. | Dec 1997 | A |
5702462 | Oberlander | Dec 1997 | A |
5711690 | Thrush et al. | Jan 1998 | A |
5711969 | Patel et al. | Jan 1998 | A |
5725556 | Moser et al. | Mar 1998 | A |
5730933 | Peterson | Mar 1998 | A |
5733337 | Carr, Jr. et al. | Mar 1998 | A |
5733868 | Peterson et al. | Mar 1998 | A |
5735897 | Buirge | Apr 1998 | A |
5735903 | Li et al. | Apr 1998 | A |
5736372 | Vacanti et al. | Apr 1998 | A |
5753267 | Badylak et al. | May 1998 | A |
5755791 | Whitson et al. | May 1998 | A |
5759190 | Vibe-Hansen et al. | Jun 1998 | A |
5759205 | Valentini | Jun 1998 | A |
5762600 | Bruchman et al. | Jun 1998 | A |
5762966 | Knapp et al. | Jun 1998 | A |
5769899 | Schwartz et al. | Jun 1998 | A |
5773577 | Cappello | Jun 1998 | A |
5788625 | Plouhar et al. | Aug 1998 | A |
5795353 | Felt | Aug 1998 | A |
5800537 | Bell | Sep 1998 | A |
5830708 | Naughton | Nov 1998 | A |
5834232 | Bishop et al. | Nov 1998 | A |
5842477 | Naughton et al. | Dec 1998 | A |
5847012 | Shalaby et al. | Dec 1998 | A |
5855610 | Vacanti et al. | Jan 1999 | A |
5855613 | Antanavich et al. | Jan 1999 | A |
5855619 | Caplan et al. | Jan 1999 | A |
5859150 | Jamiolkowski et al. | Jan 1999 | A |
5861004 | Kensey et al. | Jan 1999 | A |
5863551 | Woerly | Jan 1999 | A |
5865849 | Stone | Feb 1999 | A |
5866414 | Badylak et al. | Feb 1999 | A |
5885619 | Patel et al. | Mar 1999 | A |
5891558 | Bell et al. | Apr 1999 | A |
5899939 | Boyce et al. | May 1999 | A |
5906997 | Schwartz et al. | May 1999 | A |
5916265 | Hu | Jun 1999 | A |
5922028 | Plouhar et al. | Jul 1999 | A |
5939323 | Valentini et al. | Aug 1999 | A |
5954723 | Spetzler | Sep 1999 | A |
5954747 | Clark | Sep 1999 | A |
5955100 | Bosslet et al. | Sep 1999 | A |
5958874 | Clark et al. | Sep 1999 | A |
5968096 | Whitson et al. | Oct 1999 | A |
5971987 | Huxel et al. | Oct 1999 | A |
5980524 | Justin et al. | Nov 1999 | A |
5981802 | Katz | Nov 1999 | A |
5981825 | Brekke | Nov 1999 | A |
5989269 | Vibe-Hansen et al. | Nov 1999 | A |
5989280 | Euteneuer et al. | Nov 1999 | A |
5993475 | Lin et al. | Nov 1999 | A |
5993844 | Abraham et al. | Nov 1999 | A |
5997575 | Whitson et al. | Dec 1999 | A |
6010525 | Bonutti et al. | Jan 2000 | A |
6017301 | Schwartz et al. | Jan 2000 | A |
6017348 | Hart et al. | Jan 2000 | A |
6027744 | Vacvanti et al. | Feb 2000 | A |
6034140 | Schwartz et al. | Mar 2000 | A |
6042610 | Li et al. | Mar 2000 | A |
6051750 | Bell | Apr 2000 | A |
6056752 | Roger | May 2000 | A |
6056777 | McDowell | May 2000 | A |
6056778 | Grafton et al. | May 2000 | A |
6060640 | Pauley et al. | May 2000 | A |
6066160 | Colvin et al. | May 2000 | A |
6068648 | Cole et al. | May 2000 | A |
6077989 | Kandel et al. | Jun 2000 | A |
6080194 | Pachence et al. | Jun 2000 | A |
6093201 | Cooper et al. | Jul 2000 | A |
6098347 | Jaeger et al. | Aug 2000 | A |
6099567 | Badylak et al. | Aug 2000 | A |
6110212 | Gregory | Aug 2000 | A |
6126686 | Badylak et al. | Oct 2000 | A |
6133325 | Schwartz et al. | Oct 2000 | A |
6146385 | Torrie et al. | Nov 2000 | A |
6152935 | Kammerer et al. | Nov 2000 | A |
6153292 | Bell et al. | Nov 2000 | A |
6156044 | Kammerer et al. | Dec 2000 | A |
6165225 | Antanavich et al. | Dec 2000 | A |
6171344 | Atala | Jan 2001 | B1 |
6176880 | Plouhar et al. | Jan 2001 | B1 |
6179840 | Bowman | Jan 2001 | B1 |
6179872 | Bell et al. | Jan 2001 | B1 |
6187039 | Hiles et al. | Feb 2001 | B1 |
6197296 | Davies et al. | Mar 2001 | B1 |
6206931 | Cook et al. | Mar 2001 | B1 |
6214048 | Ito et al. | Apr 2001 | B1 |
6214049 | Gayer et al. | Apr 2001 | B1 |
6224892 | Searle | May 2001 | B1 |
6235057 | Roger et al. | May 2001 | B1 |
6242247 | Rieser et al. | Jun 2001 | B1 |
6251143 | Schwartz et al. | Jun 2001 | B1 |
6251876 | Bellini et al. | Jun 2001 | B1 |
6258124 | Darois et al. | Jul 2001 | B1 |
6264702 | Ory et al. | Jul 2001 | B1 |
6265333 | Dzenis et al. | Jul 2001 | B1 |
6267957 | Green et al. | Jul 2001 | B1 |
6270530 | Eldridge et al. | Aug 2001 | B1 |
6273893 | McAllen, III et al. | Aug 2001 | B1 |
6280473 | Lemperle et al. | Aug 2001 | B1 |
6280474 | Cassidy et al. | Aug 2001 | B1 |
6283980 | Vibe-Hansen et al. | Sep 2001 | B1 |
6288043 | Spiro et al. | Sep 2001 | B1 |
6290711 | Caspari et al. | Sep 2001 | B1 |
6293961 | Schwartz et al. | Sep 2001 | B2 |
6294041 | Boyce et al. | Sep 2001 | B1 |
6299905 | Peterson et al. | Oct 2001 | B1 |
6306156 | Clark | Oct 2001 | B1 |
6306159 | Schwartz et al. | Oct 2001 | B1 |
6306177 | Felt et al. | Oct 2001 | B1 |
6319258 | McAllen, III et al. | Nov 2001 | B1 |
6319271 | Schwartz et al. | Nov 2001 | B1 |
6326025 | Sigler et al. | Dec 2001 | B1 |
6333029 | Vyakarnam et al. | Dec 2001 | B1 |
6334872 | Termin et al. | Jan 2002 | B1 |
6355699 | Vyakarnam et al. | Mar 2002 | B1 |
6358284 | Fearnot et al. | Mar 2002 | B1 |
6364884 | Bowman et al. | Apr 2002 | B1 |
6371958 | Overaker | Apr 2002 | B1 |
6373221 | Koike et al. | Apr 2002 | B1 |
6379367 | Vibe-Hansen et al. | Apr 2002 | B1 |
6379710 | Badylak | Apr 2002 | B1 |
6383221 | Scarborough et al. | May 2002 | B1 |
6387693 | Rieser et al. | May 2002 | B2 |
6402766 | Bowman et al. | Jun 2002 | B2 |
6409764 | White et al. | Jun 2002 | B1 |
6423073 | Bowman | Jul 2002 | B2 |
6436110 | Bowman et al. | Aug 2002 | B2 |
6440444 | Boyce et al. | Aug 2002 | B2 |
6447517 | Bowman | Sep 2002 | B1 |
6451032 | Ory et al. | Sep 2002 | B1 |
6458158 | Anderson et al. | Oct 2002 | B1 |
6458383 | Chen et al. | Oct 2002 | B2 |
6464729 | Kandel | Oct 2002 | B1 |
6497650 | Nicolo | Dec 2002 | B1 |
6497707 | Bowman et al. | Dec 2002 | B1 |
6508821 | Schwartz et al. | Jan 2003 | B1 |
6517564 | Grafton et al. | Feb 2003 | B1 |
6566345 | Miller et al. | May 2003 | B2 |
6572650 | Abraham et al. | Jun 2003 | B1 |
6592623 | Bowlin et al. | Jul 2003 | B1 |
6638312 | Plouhar et al. | Oct 2003 | B2 |
6652872 | Nevo et al. | Nov 2003 | B2 |
6666892 | Hiles et al. | Dec 2003 | B2 |
6692499 | Törmäläet et al. | Feb 2004 | B2 |
6808194 | Martin | Oct 2004 | B2 |
6812221 | McKeehan et al. | Nov 2004 | B2 |
6840962 | Vacanti et al. | Jan 2005 | B1 |
6869938 | Schwartz et al. | Mar 2005 | B1 |
6989034 | Hammer et al. | Jan 2006 | B2 |
7819918 | Malaviya et al. | Oct 2010 | B2 |
7914808 | Malaviya et al. | Mar 2011 | B2 |
20010002446 | Plouhar et al. | May 2001 | A1 |
20010023373 | Plouhar et al. | Sep 2001 | A1 |
20010024658 | Chen et al. | Sep 2001 | A1 |
20010043943 | Coffey | Nov 2001 | A1 |
20020019649 | Sikora et al. | Feb 2002 | A1 |
20020031551 | Peterson et al. | Mar 2002 | A1 |
20020034533 | Peterson et al. | Mar 2002 | A1 |
20020038151 | Plouhar et al. | Mar 2002 | A1 |
20020048595 | Geistlich et al. | Apr 2002 | A1 |
20020052628 | Bowman | May 2002 | A1 |
20020090725 | Simpson et al. | Jul 2002 | A1 |
20020091444 | Yang | Jul 2002 | A1 |
20020095157 | Bowman | Jul 2002 | A1 |
20020099448 | Hiles et al. | Jul 2002 | A1 |
20020165611 | Enzerink et al. | Nov 2002 | A1 |
20020169465 | Bowman et al. | Nov 2002 | A1 |
20020173806 | Giannetti et al. | Nov 2002 | A1 |
20030014126 | Patel et al. | Jan 2003 | A1 |
20030021827 | Malaviya et al. | Jan 2003 | A1 |
20030023316 | Brown et al. | Jan 2003 | A1 |
20030032961 | Pelo et al. | Feb 2003 | A1 |
20030033021 | Plouhar et al. | Feb 2003 | A1 |
20030033022 | Plouhar et al. | Feb 2003 | A1 |
20030036797 | Malaviya et al. | Feb 2003 | A1 |
20030036801 | Schwartz et al. | Feb 2003 | A1 |
20030044444 | Malaviya et al. | Mar 2003 | A1 |
20030049299 | Malaviya et al. | Mar 2003 | A1 |
20030078617 | Schwartz et al. | Apr 2003 | A1 |
20030212447 | Euteneuer et al. | Nov 2003 | A1 |
20040059431 | Plouhar et al. | Mar 2004 | A1 |
20040143344 | Malaviya et al. | Jul 2004 | A1 |
20040166169 | Malaviya et al. | Aug 2004 | A1 |
20040220574 | Pelo et al. | Nov 2004 | A1 |
20050027307 | Schwartz et al. | Feb 2005 | A1 |
20050112248 | Galloway | May 2005 | A1 |
20050249771 | Malaviya et al. | Nov 2005 | A1 |
20050249772 | Malaviya et al. | Nov 2005 | A1 |
Number | Date | Country |
---|---|---|
0 446 105 | Jan 1992 | EP |
0591991 | Apr 1994 | EP |
0832999 | Nov 1995 | EP |
0 734 736 | Oct 1996 | EP |
1070487 | Jan 2001 | EP |
1593400 | Nov 2005 | EP |
2 215 209 | Sep 1989 | GB |
11319068 | Nov 1999 | JP |
WO 9009769 | Sep 1990 | WO |
WO 9411008 | May 1994 | WO |
WO 9505083 | Feb 1995 | WO |
WO 9522301 | Aug 1995 | WO |
WO 9506439 | Sep 1995 | WO |
9532623 | Dec 1995 | WO |
WO 9532623 | Dec 1995 | WO |
9625961 | Aug 1996 | WO |
W09624304 | Aug 1996 | WO |
WO 9624661 | Aug 1996 | WO |
WO 9705193 | Feb 1997 | WO |
9730662 | Aug 1997 | WO |
WO 9737613 | Oct 1997 | WO |
WO 9806445 | Feb 1998 | WO |
9822154 | May 1998 | WO |
WO 9822158 | May 1998 | WO |
WO 9822158 | May 1998 | WO |
WO 9830167 | Jul 1998 | WO |
WO 9834569 | Aug 1998 | WO |
WO 9840111 | Sep 1998 | WO |
WO 9903979 | Jan 1999 | WO |
WO 9943786 | Sep 1999 | WO |
WO 9947188 | Sep 1999 | WO |
0015153 | Mar 2000 | WO |
WO 0015765 | Mar 2000 | WO |
WO 0016822 | Mar 2000 | WO |
WO 0024437 | May 2000 | WO |
WO 0024437 | May 2000 | WO |
WO 0032250 | Jun 2000 | WO |
WO 0048550 | Aug 2000 | WO |
0072782 | Dec 2000 | WO |
WO 0072782 | Dec 2000 | WO |
WO 0119423 | Mar 2001 | WO |
WO 0139694 | Jun 2001 | WO |
WO 0139694 | Jun 2001 | WO |
WO 0145765 | Jun 2001 | WO |
WO 0166159 | Sep 2001 | WO |
WO 0222184 | Mar 2002 | WO |
WO 03007784 | Jan 2003 | WO |
WO 03007788 | Jan 2003 | WO |
WO 03007790 | Jan 2003 | WO |
Number | Date | Country | |
---|---|---|---|
20030036797 A1 | Feb 2003 | US |
Number | Date | Country | |
---|---|---|---|
60388713 | Jun 2002 | US | |
60305786 | Jul 2001 | US |